REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.89
+1.16%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 189.1M | 221.2M | 189.4M | 175.0M | 126.5M |
| SG&A Expense | 113.2M | 98.7M | — | — | — |
| General & Admin Expense | 40.9M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (32.6M) | — | 72.2M | 59.8M | 50.6M |
| Total Operating Expenses | 269.7M | 319.9M | 261.6M | 234.8M | 177.1M |
| Cost and Expenses | 269.7M | 319.9M | 261.6M | 234.8M | 177.1M |
| Operating Income (EBIT) | (269.7M) | (319.9M) | (261.6M) | (234.8M) | (177.1M) |
| Non-Operating | |||||
| Interest Income | 17.5M | 13.6M | 21.1M | 23.4M | 10.0M |
| Interest Expense | 12.0M | 8.9M | 7.9M | 6.7M | 4.2M |
| Net Interest Income | 5.5M | 4.8M | 13.2M | 16.7M | 5.8M |
| Other Non-Op Income/Expense | (1.9M) | 5.4M | 14.8M | 19.4M | 3.1M |
| Non-Operating Income (excl Interest) | (6.6M) | (14.3M) | (1.8M) | (1.9M) | (2.9M) |
| EBT (Pre-Tax Income) | (271.6M) | (314.5M) | (246.8M) | (215.4M) | (174.0M) |
| Income Tax Expense | (847.0K) | (551.0K) | 468.0K | 408.0K | 288.0K |
| Bottom Line | |||||
| Net Income | (271.0M) | (313.9M) | (247.3M) | (215.8M) | (174.3M) |
| Earnings from Cont. Ops | (270.7M) | (313.9M) | (247.3M) | (215.8M) | (174.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (271.0M) | (313.9M) | (247.3M) | (215.8M) | (174.3M) |
| Per Share | |||||
| Basic EPS | ($2.79) | ($3.38) | ($3.07) | ($3.24) | ($2.99) |
| Diluted EPS | ($2.79) | ($3.38) | ($3.07) | ($3.24) | ($2.99) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 105.2M | 92.8M | 80.6M | 66.6M | 58.2M |
| Diluted Shares Outstanding | 105.2M | 92.8M | 80.6M | 66.6M | 58.2M |
| Profitability Metrics | |||||
| EBITDA | (258.8M) | (302.3M) | (256.4M) | (230.2M) | (171.7M) |
| D&A | 4.3M | 3.3M | 3.5M | 2.7M | 2.4M |
| EBIT | (263.2M) | (305.6M) | (259.9M) | (232.9M) | (174.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026